Table 2.
Cohort characteristics at 24-month follow-up
| All subjects at baseline (n=292) | All subjects at follow-up (n=292) | Cases at follow-up (n=146) |
Controls at follow-up (n=146) |
P1 | P2 | |
| Total cholesterol, mg/dL | 182 (154–211) | 164 (138–196) | 166 (138–199) | 162 (137–194) | <0.001*† | 0.619† |
| HDL cholesterol, mg/dL | 39 (34–47) | 40 (34–48) | 39 (33–45) | 42 (35–52) | 0.290† | 0.033*† |
| LDL cholesterol, mg/dL | 103 (81–126) | 87 (70–112) | 92 (71–111) | 86 (70–115) | <0.001*† | 0.981† |
| HbA1c, % | 8.2 (7.6–8.9) | 7.1 (6.4–7.8) | 7.0 (6.3–8.0) | 7.1 (6.4–7.7) | <0.001*† | 0.350† |
| eGFR, mL/min | 89.30 (74.80–105.38) | 79.00 (64.20–91.00) | 79.90 (63.98–90.48) | 75.80 (64.60–94.80) | <0.001*† | 0.527† |
| ACEI and/or ARB, n (%) | 202/292 (69) | 205/258 (79) | 106/133 (80) | 99/124 (80) | 0.009*‡ | 1.000‡ |
| Antiplatelet, n (%) | 148/289 (51) | 165/257 (64) | 86/133 (65) | 79/123 (64) | 0.001*‡ | 0.658‡ |
| Statin, n (%) | 173/290 (60) | 194/258 (75) | 105/133 (79) | 89/124 (72) | <0.001*‡ | 0.043*‡ |
Variables expressed as median (IQR) or n (%).
*P < 0.05 considered significant.
†Wilcoxon signed rank test for paired subjects or repeated measures within each subject.
‡McNemar’s test for paired subjects or repeated measures within each subject.
ACEI, ACE inhibitor; ARB, angiotensin II receptor blocker; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; P1, comparison between baseline and follow-up for all subjects in the entire cohort; P2, comparison between matched cases and controls at follow-up.